Cohance Lifesciences Limited announced on January 17, 2026, the approval of a grant of 3,89,668 stock options to eligible employees under its Employee Stock Option Plan 2023 (ESOP 2023).

This grant includes 2,18,077 stock options that were issued in accordance with the Scheme of Amalgamation between erstwhile Cohance Lifesciences Limited and the Company, as approved by the National Company Law Tribunal (NCLT) on March 27, 2025.

Of the total options granted, 1,71,591 options will vest no earlier than one year and no later than ten years from the grant date, subject to the terms of the grant letter. The 2,18,077 stock options, granted in lieu of options held by employees of the Transferor Company, will vest on April 1, 2026. These options will be governed by the terms of ESOP 2023, and the period during which employees held options in the Transferor Company will be considered for determining the vesting period. The exercise period for vested options is up to three years from the vesting date.